POS0634 EVALUATION OF THE SAFETY SKILLS OF PATIENTS WITH BIOLOGICAL DMARDS AFTER A THERAPEUTIC PATIENT EDUCATION PROGRAM

• Published in: Annals of the rheumatic diseases Vol. 82; no. Suppl 1; pp. 592 - 593
• Main Authors: Bencharif, I, Bendjenna, D, Ladjouze-Rezig, A
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2023
• Subjects: Arthritis; Immunization; Inflammation; Inflammatory diseases; Patient education; Patients; Psoriatic arthritis; Questionnaires; Rheumatic diseases; Rheumatoid arthritis; Safety; Vaccination
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2023-eular.3602

BackgroundBiological DMARDs (bDMARDs) are well known cause a number of specific complications, including infectious ones. Patients receiving bDMARDs must know them and acquire self-care and safety skills in order to take charge of themselves in risky situations. This is only possible thanks to therapeutic patient education (TPE) programs in chronic Inflammatory arthritis such as rheumatoid arthritis (RA), spondyloarthritis (SpA) and Psoriatic arthritis (PsA).ObjectivesTo evaluate the impact of the therapeutic patient education program “EST-RIC” on the safety skills in patients treated with bDMARDs and on clinical parameters (Disease activity scores, compliance, number of infectious events, number of treatment stops, vaccination rate).MethodsNon-randomized clinical trial comparing the knowledge and safety skills between two cohorts of patients with RA, SpA or PsA receiving bDMARDs for at least three months in the day hospital center of CHU of Constantine: group TPE (patients joined the “EST-RIC” therapeutic education program) versus group TPE-naive (patients who did not wish to participate).The primary outcome was the acquisition of safety skills at 3 and 6 months measured by the Biosecure questionnaire (0-100 scale), a 55 item validated questionnaire assessing competences to deal with fever, infections, vaccination, and other daily life situations [1]. The secondary outcomes were disease activity scores (DAS 28 for RA and BASDAI for SpA) at 6 months, compliance (Morisky score), number of infectious events, number of treatment stops, vaccination rate at 12 months.Results450 patients were included, with mean age 41,6 ± 12,1 years old; 235 (52,2%) women; 192 (42,7%) had RA; mean disease duration 9,9 ± 6,6 years, 269 (60%) received subcutaneous bDMARDs. 240 patients in group TPE versus 210 patients in group TPE-naive. The median Biosecure score was significantly higher in the group TPE than in the group TPE-naive (75.7/100 versus 57.9/100; p<0.001) at 6 months (Table 1). There was a significant difference in disease activity scores: DAS28 and BASDAI, in rates of vaccination and discontinuation of treatment by forgetfulness. Regarding the observance to treatment or incidence of infectious events, there was no significant difference between the groups TPE and TPE-naive.ConclusionSafety is an important issue in the management of inflammatory arthritis treated with bDMARDs. In this trial, therapeutic patient education improves knowledge and safety skills of arthritis patient receiving bDMARDs, and disease activity scores.Reference[1]Gossec, et al. Joint Bone Spine 2013;80:471-6.Table 1.The median Biosecure score at 6 months.Group TPEGroup TPE-naivePMedian Biosecure score75,6657,92<0,0001Interquartile range(70,98 - 78,72)(50,96 - 65,28)MIN52,7828,80MAX87,3680,08Acknowledgements:NIL.Disclosure of InterestsNone Declared.